AbbVie Filed Patent Suits To Delay Competition, Court Told

Law360, Philadelphia (February 7, 2018, 6:40 PM EST) -- The patent lawsuits filed by AbbVie Inc. and Besins Healthcare Inc. over generic testosterone replacement treatments were “anti-competitive weapons” used to delay competition for the brand-name drug AndroGel, an attorney for the Federal Trade Commission said Wednesday while opening the bench trial in the agency’s antitrust suit in Pennsylvania federal court.

Those so-called weapons were sham litigation against Teva Pharmaceuticals USA Inc. and Perrigo Co. which reaped over $1 billion in ill-gotten monopoly profits for the brand-name drug makers, and deprived customers of lower-priced versions of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.